IL2 and melanoma: To date, IL-2 and IFN-α are the only FDA-approved cytokines as adjuvant therapeutic agents for the treatment of melanoma, although other cytokines (IL-12, IL-15, IL-18, IL-21, and GM-CSF) have shown profound results in clinical settings (106, 107).